SMT201900384T1 - 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-esaidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-one per uso nel trattamento di un cancro - Google Patents
7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-esaidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-one per uso nel trattamento di un cancroInfo
- Publication number
- SMT201900384T1 SMT201900384T1 SM20190384T SMT201900384T SMT201900384T1 SM T201900384 T1 SMT201900384 T1 SM T201900384T1 SM 20190384 T SM20190384 T SM 20190384T SM T201900384 T SMT201900384 T SM T201900384T SM T201900384 T1 SMT201900384 T1 SM T201900384T1
- Authority
- SM
- San Marino
- Prior art keywords
- hexahydroimidazo
- pyrido
- methylbenzyl
- pyrimidin
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779828P | 2013-03-13 | 2013-03-13 | |
| US201361904718P | 2013-11-15 | 2013-11-15 | |
| EP14775569.8A EP2968294B1 (en) | 2013-03-13 | 2014-03-13 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
| PCT/US2014/025885 WO2014160130A1 (en) | 2013-03-13 | 2014-03-13 | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201900384T1 true SMT201900384T1 (it) | 2019-09-09 |
Family
ID=51527915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20190384T SMT201900384T1 (it) | 2013-03-13 | 2014-03-13 | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-esaidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-one per uso nel trattamento di un cancro |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9265765B2 (enExample) |
| EP (2) | EP2968294B1 (enExample) |
| JP (3) | JP6446025B2 (enExample) |
| KR (2) | KR20220123335A (enExample) |
| CN (2) | CN119954807A (enExample) |
| AU (3) | AU2014244117B2 (enExample) |
| BR (1) | BR112015023256A2 (enExample) |
| CA (2) | CA2905037C (enExample) |
| CY (1) | CY1121735T1 (enExample) |
| DK (1) | DK2968294T3 (enExample) |
| EA (1) | EA037937B1 (enExample) |
| ES (1) | ES2734568T3 (enExample) |
| HR (1) | HRP20191181T1 (enExample) |
| HU (1) | HUE044238T2 (enExample) |
| IL (2) | IL241452B (enExample) |
| LT (1) | LT2968294T (enExample) |
| ME (1) | ME03470B (enExample) |
| MX (2) | MX2015012636A (enExample) |
| NZ (2) | NZ751509A (enExample) |
| PL (1) | PL2968294T3 (enExample) |
| PT (1) | PT2968294T (enExample) |
| RS (1) | RS59013B1 (enExample) |
| SG (2) | SG11201507247WA (enExample) |
| SI (1) | SI2968294T1 (enExample) |
| SM (1) | SMT201900384T1 (enExample) |
| WO (1) | WO2014160130A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65813B1 (sr) | 2011-04-29 | 2024-08-30 | Penn State Res Found | Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| ES2734568T3 (es) | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| ES2644022T3 (es) | 2013-03-14 | 2017-11-27 | Bristol-Myers Squibb Company | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| CN106163524B (zh) * | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| EP3662910B1 (en) * | 2014-03-31 | 2024-09-18 | The Scripps Research Institute | Pharmacophore for trail induction |
| JP6802172B2 (ja) * | 2015-01-30 | 2020-12-16 | オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| CN107787373B (zh) | 2015-08-17 | 2021-11-26 | 库拉肿瘤学公司 | 法尼基转移酶抑制剂在制备用于治疗癌症的药物中的用途 |
| KR20170037260A (ko) | 2015-09-25 | 2017-04-04 | 현대자동차주식회사 | 차량용 배터리 시스템 및 그 제어 방법 |
| BR112018015590A2 (pt) | 2016-01-29 | 2019-10-01 | Oncoceutics Inc | modulação de receptor acoplado à proteína g (gpcr) por imipridonas |
| KR102456433B1 (ko) | 2016-03-02 | 2022-10-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
| KR20170110520A (ko) * | 2016-03-23 | 2017-10-11 | 고려대학교 산학협력단 | mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물 |
| CA3058503A1 (en) | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| AU2017247006B2 (en) * | 2016-04-06 | 2022-05-12 | Noxopharm Limited | Radiotherapy improvements |
| EP3496724B8 (en) * | 2016-08-12 | 2021-11-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| HUE053927T2 (hu) | 2016-11-03 | 2021-07-28 | Kura Oncology Inc | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra |
| WO2018129080A1 (en) * | 2017-01-04 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Target genes in myc-driven neoplasia |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| IT201800004082A1 (it) * | 2018-03-29 | 2019-09-29 | Berlin Chemie Ag | Composizioni farmaceutiche antitumorali per terapia combinata |
| US20200046703A1 (en) * | 2018-08-09 | 2020-02-13 | Asymmetric Therapeutics, Llc | Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| WO2020147842A1 (zh) * | 2019-01-18 | 2020-07-23 | 南京明德新药研发有限公司 | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| JP7668033B2 (ja) * | 2019-11-28 | 2025-04-24 | ▲應▼世生物科技（南京）有限公司 | 癌の治療におけるｂｉ８５３５２０の使用 |
| WO2021142144A1 (en) | 2020-01-10 | 2021-07-15 | Immuneering Corporation | Mek inhibitors and therapeutic uses thereof |
| JP2023519990A (ja) | 2020-03-30 | 2023-05-15 | ノクソファーム リミティド | 感染に関連する炎症の治療のための方法 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| JP2012502994A (ja) | 2008-09-22 | 2012-02-02 | アムジエン・インコーポレーテツド | 治療方法 |
| EP2367425B1 (en) | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| RS65813B1 (sr) * | 2011-04-29 | 2024-08-30 | Penn State Res Found | Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| ES2734568T3 (es) | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| EP3662910B1 (en) | 2014-03-31 | 2024-09-18 | The Scripps Research Institute | Pharmacophore for trail induction |
-
2014
- 2014-03-13 ES ES14775569T patent/ES2734568T3/es active Active
- 2014-03-13 HU HUE14775569 patent/HUE044238T2/hu unknown
- 2014-03-13 EA EA201591715A patent/EA037937B1/ru unknown
- 2014-03-13 SG SG11201507247WA patent/SG11201507247WA/en unknown
- 2014-03-13 RS RS20190874A patent/RS59013B1/sr unknown
- 2014-03-13 BR BR112015023256A patent/BR112015023256A2/pt not_active Application Discontinuation
- 2014-03-13 NZ NZ751509A patent/NZ751509A/en active IP Right Revival
- 2014-03-13 WO PCT/US2014/025885 patent/WO2014160130A1/en not_active Ceased
- 2014-03-13 SI SI201431257T patent/SI2968294T1/sl unknown
- 2014-03-13 PT PT14775569T patent/PT2968294T/pt unknown
- 2014-03-13 EP EP14775569.8A patent/EP2968294B1/en active Active
- 2014-03-13 SM SM20190384T patent/SMT201900384T1/it unknown
- 2014-03-13 NZ NZ711948A patent/NZ711948A/en unknown
- 2014-03-13 AU AU2014244117A patent/AU2014244117B2/en not_active Ceased
- 2014-03-13 LT LTEP14775569.8T patent/LT2968294T/lt unknown
- 2014-03-13 US US14/208,657 patent/US9265765B2/en active Active
- 2014-03-13 HR HRP20191181TT patent/HRP20191181T1/hr unknown
- 2014-03-13 EP EP19171477.3A patent/EP3572083A1/en not_active Withdrawn
- 2014-03-13 CA CA2905037A patent/CA2905037C/en active Active
- 2014-03-13 KR KR1020227029471A patent/KR20220123335A/ko not_active Ceased
- 2014-03-13 ME MEP-2019-197A patent/ME03470B/me unknown
- 2014-03-13 MX MX2015012636A patent/MX2015012636A/es active IP Right Grant
- 2014-03-13 SG SG10201808496VA patent/SG10201808496VA/en unknown
- 2014-03-13 JP JP2016501988A patent/JP6446025B2/ja active Active
- 2014-03-13 DK DK14775569.8T patent/DK2968294T3/da active
- 2014-03-13 KR KR1020157028393A patent/KR102438135B1/ko active Active
- 2014-03-13 PL PL14775569T patent/PL2968294T3/pl unknown
- 2014-03-13 CN CN202510107155.3A patent/CN119954807A/zh active Pending
- 2014-03-13 CN CN201480022856.7A patent/CN105530937A/zh active Pending
- 2014-03-13 CA CA3204801A patent/CA3204801A1/en active Pending
-
2015
- 2015-09-10 IL IL241452A patent/IL241452B/en active IP Right Grant
- 2015-09-11 MX MX2019013643A patent/MX2019013643A/es unknown
-
2018
- 2018-06-22 JP JP2018119005A patent/JP2018184411A/ja active Pending
-
2019
- 2019-03-19 AU AU2019201896A patent/AU2019201896A1/en not_active Abandoned
- 2019-07-01 CY CY20191100687T patent/CY1121735T1/el unknown
-
2020
- 2020-06-23 IL IL275623A patent/IL275623A/en unknown
- 2020-07-01 JP JP2020114024A patent/JP2020172510A/ja active Pending
- 2020-09-14 AU AU2020233606A patent/AU2020233606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2968294T3 (pl) | 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu | |
| IL288525A (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo-[1,2-a] pyrido [3,4-e] pyrimidine-5(1h)-one, analogs and salts thereof, and methods of use for therapy | |
| IL288674B (en) | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidine-5(1h)one, its salts and methods Use | |
| IL246311A0 (en) | Pyrazolo[5,1-a]pyridine derivatives and methods of using them | |
| ZA201800485B (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| GB201516220D0 (en) | Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer |